Author:
Jagadeeshan Sankar,Suryamohan Kushal,Shin Nara,Mathukkada Sooraj,Boyko Alexandra,Melikhova Daria,Tsareva Anastasia,Yunusova Leysan,Pravdivtseva Ekaterina,Stupichev Danil,Shaposhnikov Kirill,Peterson Angela,Bednyagin Lev,Shugaev-Mendosa Eduardo,Kessler Linda,Burrows Francis,Ho Alan L.,Agrawal Nishant,Pearson Alexander T.,Izumchenko Evgeny,Cole Grayson,Elkabets Moshe,Rosenberg Ari J.
Funder
National Institutes of Health
Council for Higher Education
National Cancer Institute
Israel Cancer Research Fund
University of Chicago
National Natural Science Foundation of China
Israel Science Foundation
Reference41 articles.
1. Head and neck cancer;Mody;Lancet,2021
2. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study;Cohen;Lancet,2019
3. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;Lancet,2019
4. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N Engl J Med,2016
5. Characterization of molecular subtypes in head and neck squamous cell carcinoma with distinct prognosis and treatment responsiveness;Zhang;Front Cell Dev Biol,2021